Clinical Trials on Grade B Acute Graft Versus Host Disease

Total 5426 results

Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
Massachusetts General Hospital
American Cancer Society, Inc.

Completed

FMT In High-Risk Acute GVHD After ALLO HCT

Hematopoietic Cell Transplantation | Acute Graft-Versus-Host Disease (Gvhd) Grade | Fecal Microbiota Transplant

United States
Shanghai Children's Medical Center
Chinese University of Hong Kong; Nanfang Hospital of Southern Medical University and other collaborators

Recruiting

TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Relapsed Pediatric AML | Relapsed Pediatric ALL | Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)

China
Jazz Pharmaceuticals

Completed

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Acute-graft-versus-host Disease | Graft-versus-host Disease

United States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
University of Liege

Terminated

Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Chronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host Disease

Belgium
Jonsson Comprehensive Cancer Center

Withdrawn

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Acute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

United States
AltruBio Inc.

Completed

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Steroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host Disease

United States
Shenzhen Xbiome Biotech Co., Ltd.
Beijing Improve-Quality Tech.Co., Ltd.

Recruiting

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Acute-graft-versus-host Disease

China
Cytopeutics Sdn. Bhd.
Universiti Tunku Abdul Rahman

Active, not recruiting

UCMSCs as Front-line Approach of Treatment for Patients With aGVHD (GVHD Cyto-MSC)

Acute-graft-versus-host Disease

Malaysia
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
Central Hospital, Nancy, France

Unknown

A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease (PCE-aGVHD)

Acute-graft-versus-host Disease
Mallinckrodt
PRA Health Sciences

Terminated

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

Acute Graft-versus-Host Disease

United States, Canada, Germany, United Kingdom, Australia, Austria, Belgium, Italy, France, Netherlands, Switzerland
moshe yeshurun

Unknown

Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

Acute-graft-versus-host Disease

Israel
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaborators

Unknown

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Acute Graft-versus-host Disease

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaborators

Unknown

Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease

Acute Graft-versus-host Disease

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Acute Graft-Versus-Host Disease

China
ASC Therapeutics

Not yet recruiting

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Acute-graft-versus-host Disease
The First Affiliated Hospital of Soochow University

Recruiting

Fecal Microbiota Transplantation in Gut aGVHD Treated

Acute-graft-versus-host Disease

China
Genentech, Inc.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft-versus-host Disease

United States
Genentech, Inc.

Terminated

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-versus-host Disease

United States, Canada
Masonic Cancer Center, University of Minnesota

Recruiting

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Acute-graft-versus-host Disease

United States
Universitätsklinikum Hamburg-Eppendorf
Mallinckrodt; University Medical Center Regensburg; Arbeitskreis Klinische Forschung...

Recruiting

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

Acute-graft-versus-host Disease

Germany, Austria
Nanfang Hospital, Southern Medical University

Active, not recruiting

Donor Neutrophil Subsets to Predict the Risk of aGVHD

Acute Graft-versus-Host Disease

China
Lee Dupuis
C17 Council

Completed

Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT

Acute-graft-versus-host Disease

Canada
Peking University People's Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Unknown

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)

Acute-graft-versus-host Disease

China
Peking University People's Hospital

Unknown

Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

Acute Graft-versus-host Disease

China
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
John Levine

Completed

Itacitinib for Low Risk GVHD

GVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-disease

United States
Equillium
Biocon Limited

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD (EQUATE)

GVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host Disease

United States
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
medac GmbH

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)

Steroid-refractory Acute Graft-versus-host Disease

Spain, Germany, France, Poland, Sweden
Novartis Pharmaceuticals

Not yet recruiting

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Steroid-refractory Acute Graft Versus Host Disease
medac GmbH

Recruiting

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (BALDER)

Steroid-refractory Acute Graft-versus-host Disease

Germany, Spain, France, Poland, Italy
Qilu Hospital of Shandong University
Peking University People's Hospital

Recruiting

Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT

Acute Graft Versus Host Disease in Intestine

China
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (1802)

Steroid-Refractory Acute Graft Versus Host Disease

United States
ElsaLys Biotech

Available

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Steroid Resistant Acute Graft Versus Host Disease

France
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

GVHD | Graft-versus-host-disease | GVHD, Acute

United States
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

Steroid-Refractory Acute Graft Versus Host Disease

United States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Regimmune Corporation

Completed

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHD

United States
Shandong Provincial Hospital

Recruiting

HBOT in the Treatment and Prevention of aGVHD

Hyperbaric Oxygen Therapy | Acute-graft-versus-host Disease

China
Nanfang Hospital of Southern Medical University

Unknown

Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD

Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease

China
Ohio State University Comprehensive Cancer Center

Recruiting

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

Acute Graft-versus-Host Disease | Allogeneic Stem Cell Transplant

United States
IRCCS Burlo Garofolo

Completed

Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT

Acute Graft-versus-host Disease

Italy
Leland Metheny

Withdrawn

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)

United States
Anhui Provincial Hospital

Recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; Shenzhen People... and other collaborators

Recruiting

Sitagliptin for Prevention of aGVHD After Alternative Donor Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation | Acute-graft-versus-host Disease

China
MaaT Pharma

Recruiting

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

Spain, France, Germany, Austria, Belgium, Italy
The First Affiliated Hospital of Soochow University

Recruiting

Abatacept s.c. for aGVHD Prevention in Haplo-HCT

Prevention | Acute-graft-versus-host Disease | Abatacept | Haplo-identical HCT

China
MaaT Pharma

Available

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

France

Clinical Trials on Grade B Acute Graft Versus Host Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations